SG Americas Securities
KPTI icon

SG Americas Securities’s Karyopharm Therapeutics KPTI Stock Holding History

SG Americas Securities’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,895
Closed -$64K – 3209
2023
Q4 		$64K Buy
4,895
+3,656
+295% +$49.3K ﹤0.01% 2881
2023
Q3 		$25K Buy
1,239
+248
+25% +$5.57K ﹤0.01% 3025
2023
Q2 		$27K Sell
991
-1,400
-59% -$60.3K ﹤0.01% 2165
2023
Q1 		$140K Buy
+2,391
New +$118K ﹤0.01% 2688
2022
Q4 		– Sell
-1,014
Closed -$83K – 3224
2022
Q3 		$83K Sell
1,014
-5,068
-83% -$379K ﹤0.01% 2899
2022
Q2 		$411K Buy
+6,082
New +$558K ﹤0.01% 2133
2022
Q1 		– Sell
-1,581
Closed -$152K – 3222
2021
Q4 		$152K Sell
1,581
-1,232
-44% -$123K ﹤0.01% 2818
2021
Q3 		$246K Buy
+2,813
New +$292K ﹤0.01% 3082
2021
Q2 		– Sell
-1,085
Closed -$171K – 3056
2021
Q1 		$171K Buy
+1,085
New +$229K ﹤0.01% 2779
2020
Q4 		– Sell
-4,258
Closed -$932K – 3408
2020
Q3 		$932K Buy
4,258
+2,868
+206% +$702K 0.01% 1224
2020
Q2 		$395K Buy
1,390
+585
+73% +$173K ﹤0.01% 2301
2020
Q1 		$232K Buy
805
+224
+39% +$61.8K ﹤0.01% 2405
2019
Q4 		$167K Buy
+581
New +$126K ﹤0.01% 2611
2018
Q1 		– Sell
-673
Closed -$97K – 3412
2017
Q4 		$97K Sell
673
-201
-23% -$32.3K ﹤0.01% 2867
2017
Q3 		$144K Buy
874
+191
+28% +$27.4K ﹤0.01% 2882
2017
Q2 		$93K Buy
+683
New +$101K ﹤0.01% 2940
2017
Q1 		– Sell
-1,023
Closed -$144K – 3430
2016
Q4 		$144K Buy
+1,023
New +$138K ﹤0.01% 2607
2015
Q4 		– Sell
-1,032
Closed -$163K – 2853
2015
Q3 		$163K Buy
+1,032
New +$276K ﹤0.01% 1578
2015
Q1 		– Sell
-355
Closed -$199K – 2829
2014
Q4 		$199K Buy
355
+139
+64% +$79K ﹤0.01% 2423
2014
Q3 		$113K Sell
216
-48
-18% -$27.1K ﹤0.01% 2313
2014
Q2 		$184K Buy
+264
New +$123K ﹤0.01% 2064

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SG Americas Securities's KPTI Position: Q1 2024 in Review

SG Americas Securities sold out of Karyopharm Therapeutics (KPTI) in Q1 2024, closing a stake of 4,895 shares — an estimated $64K sold.

SG Americas Securities first reported a position in KPTI in Q2 2014 and held it in 21 quarters. The position peaked at $932K in Q3 2020. 113 funds tracked by Wall St. Rank hold KPTI as of Q1 2024.

  • SG Americas Securities reported no remaining Karyopharm Therapeutics position as of Q1 2024 after selling out during the quarter.
  • SG Americas Securities sold 4,895 Karyopharm Therapeutics shares in Q1 2024, an estimated $64K.
  • SG Americas Securities first reported a position in Karyopharm Therapeutics in Q2 2014 and held it in 21 quarters.
  • SG Americas Securities's Karyopharm Therapeutics position peaked at $932K in Q3 2020.
  • 113 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2024.

Based on SG Americas Securities's 13F filing for Q1 2024, filed 6 May 2024.